Immune Boost Capital (IBC) is the philanthropic venture subsidiary of the Arthritis National Research Foundation. The mission of IBC is to invest in early promising autoimmune diagnostics and therapeutics, recycling 100% of returns to fuel future innovation.
We believe the best chance at success in bringing cures and treatments to arthritis and related autoimmune disease is to invest in early stage promising therapies, companies, and technologies, and help guide and mentor them through development.
ANRF is a financial and scientific partner. IBC remains operationally independent, guided by experienced investors, scientists, and healthcare leaders.
Board of Directors comprised of seasoned biotech executives, investors, and scientists; rigorous due diligence aligned with institutional venture standards.
Autoimmune & inflammatory diseases-diagnostics and therapeutics at or before preclinical proof-of-concept.
We welcome outreach from emerging companies as well as academic spinouts. Share a concise non-confidential overview (problem, solution, evidence, development plan, financing requirements and timeline to first milestone) and we’ll follow up.
Principal, Trefoil Therapeutics
CEO, ANRF
Chair, Corevitas
MD, PhD Treasurer, Abata Therapeutics
Secretary, Life Science Venture Capital/Biotech venture investor
Retired, Dell Technologies
Corevitas
Advisor, Certara
